New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and